Celiac Disease Diagnosis and Management

Celiac disease is an immune‐mediated enteropathy precipitated by the ingestion of gluten in genetically predisposed individuals. Central to its pathogenesis is the deamidation of gluten peptides by tissue transglutaminase 2, which enhances their presentation by HLA‐DQ2 and HLA‐DQ8 molecules to CD4+ T cells. Clinically, patients may present with gastrointestinal symptoms such as diarrhoea, bloating and malabsorption, or with extraintestinal manifestations including anaemia, dermatitis herpetiformis and neurological features. Diagnosis rests on the demonstration of specific serological markers—anti‐tissue transglutaminase and anti‐endomysial antibodies—coupled with histological evidence of villous atrophy and crypt hyperplasia on duodenal biopsy. In selected paediatric cases with strong serology and genetic predisposition, biopsy may be omitted according to recent guidelines. The cornerstone of management is a lifelong gluten-free diet, which usually induces mucosal healing and symptom resolution. Emerging therapeutic strategies aim to inhibit TG2 activity, to block antigen presentation or to modulate the gut microbiota. Monitoring compliance and nutrient status, as well as screening for associated autoimmune conditions, form integral components of long-term care.

Research from Nature Portfolio

Recent studies have elucidated molecular interventions that prevent gluten-induced mucosal injury. A trial of an oral transglutaminase 2 inhibitor demonstrated preservation of epithelial integrity and suppression of interferon-γ signatures during gluten challenge, supporting TG2 blockade as a viable adjunct to dietary therapy. Structural and functional characterisation of a neutralising antibody directed against multiple gluten peptide–HLA-DQ2.5 complexes has revealed broad reactivity and effective blockade of antigen presentation in preclinical models, offering a targeted immunotherapeutic approach that spares systemic immunity. These findings open new avenues for pharmacological management beyond dietary restriction.

Celiac Disease Diagnosis and Management publication trend

The graph below shows the total number of articles in celiac disease diagnosis and management across all publications each year (not limited to Nature Index journals).

Technical terms

Tissue transglutaminase 2 (TG2): An enzyme that deamidates gluten peptides, enhancing their immunogenicity in celiac disease.

HLA-DQ2/HLA-DQ8: Human leucocyte antigen class II molecules that present deamidated gluten peptides to CD4+ T cells.

Serology: Blood tests detecting disease‐specific antibodies, notably anti‐tissue transglutaminase and anti‐endomysial antibodies.

Villous atrophy: Flattening of intestinal villi seen on duodenal biopsy, indicating mucosal damage.

Gluten-free diet (GFD): Lifelong elimination of wheat, barley and rye proteins to prevent immune activation and allow mucosal recovery.

References

1. Transcriptomic analysis of intestine following administration of a transglutaminase 2 inhibitor to prevent gluten-induced intestinal damage in celiac disease. Nature Immunology (2024).
2. Characterizations of a neutralizing antibody broadly reactive to multiple gluten peptide:HLA-DQ2.5 complexes in the context of celiac disease. Nature Communications (2023).
3. Celiac disease: a comprehensive current review. BMC Medicine (2019).
4. Gluten-Free Diet: Gaps and Needs for a Healthier Diet. Nutrients (2019).